This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
Upon completion of this activity, participants should be able to:
Identify SDOH that affect outcomes in CV and NVAF management
Apply strategies to address SDOH in clinical practice to improve the management of NVAF
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Keith C. Ferdinand, MD, FACC, FAHA: has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.
David S. Kountz, MD has no relevant conflicts of interest to report.
Darcy Theisen, NP has no relevant conflicts of interest to report.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
This program has been made available online.